Kuros statement on media inquiry concerning former Board member
MWN-AI** Summary
On September 18, 2025, Kuros Biosciences issued a statement addressing media inquiries regarding the recent resignation of Albert Arp, a former Board member. The company has become aware of a potential upcoming publication in a Dutch financial media outlet alleging that Arp resigned due to misconduct related to the sharing of price-sensitive information with a third party not affiliated with Kuros. In response, Kuros is currently conducting an internal investigation to delve into these allegations.
Kuros emphasized that the situation pertains solely to Arp in his personal capacity and does not impact the company's strategic direction, financial health, or ongoing operations. This clarification aims to mitigate any potential investor concerns and maintain transparency during this period of inquiry.
The statement also briefly highlighted Kuros’ position as an innovator in next-generation bone healing technologies, particularly through its flagship product, MagnetOs. The product has demonstrated promising results in clinical studies, achieving significantly higher fusion rates compared to traditional methods. Emphasizing its advanced technology and safety profile, Kuros continues to focus on delivering innovative biologic solutions for improved surgical outcomes.
For further questions or clarifications, Kurus has provided contact details for its Investor Relations department, signaling its commitment to stakeholder communication and transparency.
Kuros Biosciences, headquartered in Switzerland, operates with a global footprint, dedicated to the research and development of cutting-edge biologic technologies in the orthopedic sector. The company is publicly listed on the SIX Swiss Exchange.
This statement is accompanied by standard disclaimers concerning forward-looking statements, reminding readers about the inherent risks and uncertainties associated with potential future outcomes in the business landscape.
MWN-AI** Analysis
On September 18, 2025, Kuros Biosciences responded to media inquiries concerning the resignation of former board member Albert Arp amidst allegations of illicit information sharing. While the company affirms that this incident pertains solely to Arp's personal actions and will not affect Kuros's strategic direction, financial results, or operational capabilities, this situation invites careful scrutiny from investors.
The resignation of a board member, particularly under controversial circumstances, can create uncertainty about governance and operational integrity, posing potential risks to brand reputation and stakeholder confidence. However, Kuros has taken proactive measures by conducting an internal investigation to clarify the situation, which reflects a commitment to transparency and accountability. This is a positive indication for investors, as it showcases a responsible approach to governance.
From a market perspective, investors should monitor how this incident shapes public perception and KURO's stock performance. If the internal investigation concludes without significant findings and the company demonstrates consistent operational performance—as seen through its innovative products like MagnetOs—then the stock could rebound quickly from any initial sell-off. On the other hand, prolonged uncertainty could weigh on the stock’s value.
Additionally, given Kuros's focus on next-generation bone healing technologies and its established reputation within the medical technology field, stakeholders should consider the firm's long-term growth potential beyond this immediate incident. The approval and differentiation of MagnetOs in clinical applications are promising aspects for revenue growth.
In summary, while the situation presents short-term risks, the long-term fundamentals of Kuros remain strong. Investors should weigh the potential for recovery against the backdrop of the company's operational stability and market position in bone healing technologies. Caution is warranted, but opportunities for growth persist.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules
Kuros statement on media inquiry concerning former Board member
Schlieren (Zurich), Switzerland, September 18, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, has become aware of a possible imminent publication in a Dutch financial media outlet regarding the recent resignation of Albert Arp, a former member of the company’s Board of Directors. Kuros has received inquiries from the media outlet regarding an allegation that Albert Arp resigned due to an illicit sharing of price-sensitive information with a third party unrelated to the corporate bodies of Kuros. Kuros is currently conducting an internal investigation regarding this allegation. We would like to clarify that this matter relates to the individual in his personal capacity and that it has no impact on the company’s strategic direction, financial results or operational activities.
For further information, please contact:
Kuros Biosciences AG
| Alexandre Müller | Daniel Geiger |
| Investor Relations | Chief Financial Officer |
| Tel +41 43 268 32 31 | Tel +41 44 733 47 41 |
| IR@kurosbio.com | daniel.geiger@kurosbio.com |
About MagnetOs
Growing bone with MagnetOs TM gives surgeons confidence where it matters most – delivering predictable fusion outcomes. 1 In a Level I human clinical study published in Spine, MagnetOs achieved nearly twice the fusion rate (79% vs. 47%) of autograft in posterolateral fusions (PLFs). 1 Among active smokers – who made up 1 in 5 patients – the fusion difference between MagnetOs and autograft was even more dramatic. *† 1,2 MagnetOs grows bone on its own thanks to NeedleGrip TM – a proprietary submicron surface technology that harnesses the immune system to stimulate bone growth, without added cells or growth factors. ‡§ 3-8 Ready-to-use, easy to mold, and reliably staying put 9 , MagnetOs carries no intrinsic risk of human tissue-related disease transmission and is FDA cleared for use throughout the spine, including interbody procedures. ¶ 5-8
Indications Statement
Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings, and precautions.
About Kuros Biosciences
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOs TM , is a unique advanced bone graft that has already been used across four continents. For more information on the company, its products and pipeline, visit kurosbio.com .
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
* 19 of initial 100 patients were active smokers.
† Radiographic fusion data of the smoker subgroup were not statistically analyzed as a subgroup and were not included in the peer-reviewed publication of the study. 2
‡ Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com.
§ MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.
¶ MagnetOs must also be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler. MagnetOs Flex Matrix must be hydrated with BMA & mixed with autograft in posterolateral spine & intervertebral disc space. MagnetOs Granules must be hydrated with blood in the intervertebral disc space.
- Stempels, et al. Spine . 2024;49(19):1323-1331.
- van Dijk, LA. 24th SGS Annual Meeting (Swiss Society of Spinal Surgery). Basel, Switzerland. Aug 2024.
- van Dijk, et al. eCM . 2021;41:756-73.
- van Dijk, et al. J Immunol Regen Med . 2023;19:100070.
- Instructions for Use (IFU) MagnetOs Granules.
- Instructions for Use (IFU) MagnetOs Putty.
- Instructions for Use (IFU) MagnetOs Easypack Putty.
- Instructions for Use (IFU) MagnetOs Flex Matrix.
- Data on file. MagnetOs Putty and MagnetOs Easypack Putty.
Attachment
FAQ**
How does Kuros Biosciences Ltd CSBTF plan to mitigate any potential reputational impact from the allegations involving former Board member Albert Arp's resignation?
What specific measures is Kuros Biosciences Ltd CSBTF taking during its internal investigation to address the allegations of illicit information sharing by Albert Arp?
Can Kuros Biosciences Ltd CSBTF provide assurances that Albert Arp's resignation will not affect the ongoing development or market strategies of its product MagnetOs?
How might Kuros Biosciences Ltd CSBTF communicate any significant findings from the internal investigation to investors and stakeholders to maintain transparency and trust?
**MWN-AI FAQ is based on asking OpenAI questions about Kuros Biosciences Ltd (OTC: CSBTF).
NASDAQ: CSBTF
CSBTF Trading
0.0% G/L:
$32 Last:
250 Volume:
$32 Open:
